- Meeting abstract
- Open Access
P01-032 – Characterization of genetic-negative FMF
© Ben-Zvi et al; licensee BioMed Central Ltd. 2013
- Published: 8 November 2013
- Genetic Testing
- Familial Mediterranean Fever
- Routine Clinic
- Average Dose
Up to 20 percent of FMF cohorts consist of patients fulfilling the diagnostic criteria of familial Mediterranean fever, yet carry no MEFV mutations (genetic-negative). The phenotype of these patients has been poorly characterized.
To define clinical and demographic parameters of genetic negative FMF.
In this observational comparative study, 47 sequential genetic negative FMF patients and 78 sequential genetic positive (for at least one allele) FMF control patients were compared using a comprehensive questionnaire completed at the time of their routine clinic visit, using direct questioning and patients' files. The definition of FMF was based on our clinical tool, widely accepted for FMF diagnosis. Absence of the 5 most common MEFV mutations in routine genetic testing of FMF was considered genetic negative FMF. Disease severity was determined by Mor criteria.
The mutation-negative and mutation positive cohorts differed respectively on the age of disease onset (19.6 vs. 10.1 years, p<0.001), family history of FMF (44% vs. 76.9%, p<0.001), rate of severe disease (23.4% vs. 64.1%, p<0.001), and rate of erysipelas-like erythema which was higher in the control group (p=0.024). There was a trend for diagnosis delay (9.95 years vs. 6.68 (p=0.08). There were no significant differences in gender and in a wide array of clinical manifestations. The average dose of colchicine, the response to treatment and the rate of chronic manifestation of FMF were also comparable between the two patient groups.
The FMF specific phenotype manifested in mutation-negative FMF, together with low prevalence of family history, suggest the occurrence of a de-novo genetic event downstream the MEFV related pathway.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.